Search Results
Sep 10, 2026, 09:00 ET NEURELIS CEO CRAIG CHAMBLISS TO PRESENT KEYNOTE AT THE 14TH ANNUAL OUTSOURCING IN CLINICAL TRIALS SOUTHERN CALIFORNIA 2026 CONFERENCE
Hypersensitivity to diazepamAcute narrow-angle glaucomaCentral Nervous System (CNS) Depression Benzodiazepines, including VALTOCO, may produce CNS depression. Caution patients against engaging in hazardous activities requiring mental alertness, such as operating
More news about: Neurelis, Inc.
Sep 10, 2026, 07:53 ET Vincere Biosciences Awarded $2.7 Million NIH Grant to Advance USP30 Inhibitor for Acute Kidney Injury
separately advancing a CNS-penetrant USP30 inhibitor for Parkinson's disease, supported by a $5 million award from The Michael J. Fox Foundation, demonstrating the potential to develop molecules with diverse properties from the same mechanistic platform for distinct CNS and peripheral indications."One
More news about: Vincere Biosciences
Sep 10, 2026, 07:00 ET BioLineRx and Hemispherian AS to Present Encouraging GLIX1 Preclinical Efficacy Data and its Phase 1/2a Trial Design at the 21st Meeting of the European Association of Neuro-Oncology (EANO 2026)
biochemical assays, in vitro, and in vivo xenograft models. In mice, GLIX1 achieved brain exposures at 68-85% of plasma levels, supporting CNS penetration. In GBM genomic 5hmC is markedly reduced versus healthy brain tissue, reflecting impaired TET2 activity. Together, these data provide a strong
More news about: BioLineRx Ltd.; Hemispherian AS
Sep 09, 2026, 16:25 ET Cohen & Steers Announces Preliminary Assets Under Management and Net Flows for August 2026
NEW YORK, Sept. 9, 2026 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) today reported preliminary assets under management of $101.0 billion at August 31, 2026, a decrease of $1.5 billion from assets under management of
More news about: Cohen & Steers, Inc.
Sep 09, 2026, 10:31 ET Waldenström Macroglobulinemia Market to Gain Momentum During the Forecast Period (2026-2036) Due to Launch of Novel Drug Classes Including BTK Degraders, Non-covalent BTKi, BCL-2 Inhibitors, and Targeted Radiotherapeutics | DelveInsight
accumulation may also offer greater dosing convenience and improved treatment flexibility for patients.NURIX's NX-5948 is an orally administered, CNS-penetrating small-molecule degrader targeting Bruton's tyrosine kinase (BTK), currently under investigation for the treatment of chronic lymphocytic
More news about: DelveInsight Business Research, LLP
Sep 08, 2026, 08:00 ET Johnson & Johnson spotlights new neuropsychiatry data across bipolar mania, depression and schizophrenia at Psych Congress 2026
SPRAVATO® with certain medicines may cause side effects. Especially tell your healthcare provider if you take central nervous system (CNS) depressants, psychostimulants, or monoamine oxidase inhibitors (MAOIs) medicines. Keep a list of them to show to your healthcare provider and pharmacist
More news about: Johnson & Johnson
Sep 07, 2026, 05:47 ET Produk Unggulan Pegunungan Guizhou Tampil di Festival Panen Shanghai
SHANGHAI, 7 September 2026 /PRNewswire/ -- Artikel berita dari CNS: China Farmers' Harvest Festival Golden-Autumn Consumption Season 2026 berlangsung di Shanghai pada 4-6 September. Sebagai salah satu pusat perdagangan internasional, Shanghai menjadi etalase global bagi produk-produk pertanian unggulan
More news about: CNS
Sep 06, 2026, 20:01 ET Harbour BioMed Successfully Included in the Stock Connect, Reinforcing Capital Market Recognition
nearly 30 differentiated drug candidates across multiple therapeutic areas, including immunology, oncology, metabolism, and the central nervous system (CNS), with several molecules having already entered clinical trials or regulatory submission stages. Batoclimab (HBM9161), the Company's lead asset, has
More news about: Harbour BioMed
Sep 06, 2026, 12:15 ET Các sản phẩm vùng núi mang thương hiệu Quý Châu nổi bật tại sự kiện Lễ hội Thu hoạch
THƯỢNG HẢI, ngày 7 tháng 9 năm 2026 /PRNewswire/ -- Bản tin từ CNS: Mùa tiêu dùng Mùa thu vàng của Lễ hội Thu hoạch Nông dân Trung Quốc 2026 đã diễn ra tại Thượng Hải từ ngày 4 đến ngày 6 tháng 9. Là một trung tâm thương mại quốc tế quan trọng, Thượng Hải đóng vai trò là nền tảng toàn cầu cho các
More news about: CNS
Sep 03, 2026, 12:23 ET Cipla Announces Exclusive Partnership with Qilu Pharmaceutical for the Licensing and Supply of Biosimilar to Keytruda® (Pembrolizumab) in the US
Africa, North America, and key regulated and emerging markets. Our strengths in the respiratory, antiretroviral, urology, cardiology, anti-infective and CNS segments are well-known. Our 48 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms
More news about: Cipla
Sep 02, 2026, 07:15 ET Transpire Bio to Participate in Upcoming Healthcare Investor Conferences During September
Pulmonary Fibrosis (IPF), Progressive Pulmonary Fibrosis (PPF), Pulmonary Arterial Hypertension (PAH), Diabetes, Obesity, and Central Nervous System (CNS) indications. For more information, please visit
More news about: Transpire Bio
Sep 02, 2026, 06:00 ET NovaGo Therapeutics Closes USD 30 Million Series B Financing to Advance Proof-of-Concept Study in Acute Spinal Cord Injury
biopharmaceutical company building next-generation antibody therapeutics. The company pioneers amyloid depletion as a novel therapeutic mechanism to treat CNS and related protein aggregation diseases including Alzheimer's disease, amyotrophic lateral sclerosis and ATTR cardiomyopathy. Neurimmune discovered
More news about: NovaGo Therapeutics
Sep 02, 2026, 06:00 ET NovaGo Therapeutics Closes USD 30 Million Series B Financing to Advance Proof-of-Concept Study in Acute Spinal Cord Injury
biopharmaceutical company building next-generation antibody therapeutics. The company pioneers amyloid depletion as a novel therapeutic mechanism to treat CNS and related protein aggregation diseases including Alzheimer's disease, amyotrophic lateral sclerosis and ATTR cardiomyopathy. Neurimmune discovered
More news about: NovaGo Therapeutics
Aug 31, 2026, 09:47 ET Cohen & Steers and Trademark Acquire Oak Hill Plaza Shopping Center in Austin, Texas
NEW YORK, Aug. 31, 2026 /PRNewswire/ -- Cohen & Steers (NYSE: CNS) announced today that the Cohen & Steers Real Estate Opportunities Fund (REOF) has acquired Oak Hill Plaza, a shopping center in Austin, Texas. The acquisition
More news about: Cohen & Steers, Inc.
Aug 31, 2026, 08:00 ET LG CNS Targets U.S. Ad Market with Agentic AI-Powered Marketing Solution
said BY Kim, Head of Solution Business Unit at LG CNS. "LG CNS will continue to leverage the success of LG Optapex to establish itself as a key AX partner supporting the growth of our clients' e-commerce businesses."About LG CNSLG CNS is a leading Korean AX (AI Transformation) company
More news about: LG CNS
Aug 28, 2026, 17:51 ET Cohen & Steers Infrastructure Fund, Inc. (UTF) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.com Symbol: (NYSE: CNS)
More news about: Cohen & Steers, Inc.
Aug 28, 2026, 17:47 ET Cohen & Steers Closed-End Opportunity Fund, Inc. (FOF) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.com Symbol: (NYSE: CNS)
More news about: Cohen & Steers, Inc.
Aug 28, 2026, 17:26 ET Cohen & Steers Quality Income Realty Fund, Inc. (RQI) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.comSymbol: (NYSE: CNS)
More news about: Cohen & Steers, Inc.
Aug 28, 2026, 17:13 ET Cohen & Steers Total Return Realty Fund, Inc. (RFI) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.comSymbol: (NYSE: CNS)
More news about: Cohen & Steers, Inc.
Aug 28, 2026, 16:59 ET Cohen & Steers REIT and Preferred and Income Fund, Inc. (RNP) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.comSymbol: (NYSE: CNS)
More news about: Cohen & Steers, Inc.
Aug 28, 2026, 09:00 ET Grand Opening of $750M CANXPORT Logistics Hub a Triumph for Canadian Trade
is a part of the momentum building at Prince Rupert, creating new opportunities and connecting Canadian trade with global markets more efficiently. CN's investments in Prince Rupert, including the Zanardi Rapids Bridge Project, expand capacity and enhance the competitiveness of this important gateway."
More news about: Prince Rupert Port Authority
Aug 27, 2026, 22:44 ET Akeso 2026 Interim Results: Strong Commercialization Momentum; IO2.0+ Global Strategy Redefining Clinical Standards; Bispecific Advancement in ADC, I&I and Alzheimer's
bispecific/multispecific candidates expected to enter the clinic in the next year.Entering the Bispecific Era in Immunology, CNS, and Respiratory DiseasesIn autoimmune, respiratory, and CNS diseases, Akeso is leveraging its expertise in bispecific and multispecific antibody development, with strategic
More news about: Akeso, Inc.
Aug 27, 2026, 10:04 ET Harbour BioMed Reports 2026 Interim Results: Three Integrated Growth Engines Accelerate Execution of Its Platform-Based Strategy
LET003 has advanced to the IND-enabling stage, with an IND submission expected in the third quarter of 2026.CNS Disease Programs: the Company is advancing a next-generation CNS pipeline focused on Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders. Multiple programs
More news about: Harbour BioMed
Aug 27, 2026, 08:15 ET Psilera Appoints Neuroscience Veteran Allyson Gage, PhD, as Vice President, Clinical Development to Lead Upcoming Phase 1 Clinical Trial
to Psilera, with a track record of advancing numerous compounds through FDA IND approval. Her expertise in biomarker identification and evaluation in CNS indications, small molecules, biologics, and cell therapies ideally positions her to lead Psilera's Phase 1 trial as VP, Clinical Development."Psilera
More news about: Psilera, Inc.
Aug 26, 2026, 10:49 ET Graviton BioScience Corporation Announces Publication of Positive Ph1b Trial Results for GV101 (TDI01) in Chronic Graft versus Host Disease in Signal Transduction and Targeted Therapy, by Beijing Tide Pharmaceutical
best-in-class therapeutics for treating metabolic, CNS, inflammatory, fibrotic, and other disease indications. Graviton has developed a portfolio of selective ROCK2 inhibitors among other safe, innovative, and novel therapies for patients with fibrotic, autoimmune, and CNS diseases. GV101 is in clinical studies,
More news about: Graviton BioScience Corporation